Get hold of yourself...

Biotech stocks can be risky, but people who know how to manage them can see big gains.‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  [Profit Trends]( SPONSORED [Virginia Stock-Picking Millionaire Breaks No. 1 Rule of Investing...]( He bought Apple 22 years ago... Amazon 13 years ago... and Netflix more than a decade ago. Now one of the world's greatest stock pickers is breaking the No. 1 rule of investing... and targeting a $3 stock that trades under a secret name. [See him explain his crazy approach live on stage here.](  Editor's Note: The truth is, things may not be as bad as they seem... In fact, in some cases, we're no worse off than we were in 2019. According to Renaissance Capital, in all of 2019 there were five $200 million biotech IPOs. So far in 2020, there have been at least eight $200 million biotech IPOs. And analysts indicate there's no slowdown in sight. But the biotech sector has a reputation for being volatile. That's why we asked Marc Lichtenfeld, the biotech guru and income expert at our sister e-letter Wealthy Retirement, to outline ways to lower your risk when you invest in biotech. Marc just revealed a [secret biotech catalyst]( that Wall Street has been using for decades. And we all know it pays to follow the smart money... Using this catalyst, Marc believes you could double your money 12 times over the next 12 months. [Click here to watch his presentation on how to use this catalyst to cash in on biotech companies.]( - Rebecca Barshop, Senior Managing Editor  [TECH INVESTING]( How to Manage Risk in Speculative Biotech Stocks Marc Lichtenfeld | Chief Income Strategist | The Oxford Club [Marc Lichtenfeld] When most companies go public, they are somewhat mature. They typically have earnings and cash flow. Tech company [initial public offerings]( or IPOs, are a bit different. The companies are often not yet profitable. And biotech IPOs are a special animal altogether. Not only are the companies usually not profitable, but most of the time they don't even have a product on the market yet. For example, last month, [Pliant Therapeutics]( (Nasdaq: PLRX) had its IPO, raising more than $140 million. The company develops fibrosis drugs. It has one drug about to enter Phase 2 trials and has partnered with big pharma giant Novartis on a potential treatment for nonalcoholic steatohepatitis. So investors buying Pliant Therapeutics are essentially hoping that one day it will get a product approved and on the market, and that said product will sell well. When things work for these small cap [biotechs]( it can be insanely lucrative. Take Pharmacyclics, for example. The company, focused on treating cancer, went public in 1995, offering 2.15 million shares at $12 per share and raising a little more than $25 million. It wasn't until 14 years later that Pharmacyclics conducted its first human trials of ibrutinib, which went on to become the company's first FDA-approved product in 2014 and a blockbuster drug. The following year, AbbVie (NYSE: ABBV) acquired Pharmacyclics for $21 billion. If you had bought Pharmacyclics on December 7, 2009, after the company presented positive results from a Phase 1 study, you could have bought the stock for $2.35. A little more than five years later, the company announced it was being acquired and you could have sold it for $230.48. Of course, you would have had to hold on to a very speculative company for more than five years to do it. But even if you had sold pieces of the position off over the years and were left with a fraction of the original position, you would have done extremely well.  SPONSORED [One of the BEST Traders in the Entire World Is Giving Away His No. 1 Pick...]( Grab a pen and paper and [write down the ticker symbol in this video](. There are no strings attached! America's No. 1 Tech Expert is revealing the [FULL TICKER SYMBOL]( of his favorite stock pick in 2020.   Pharmacyclics is the exception though, not the rule. Most early-stage biotech companies never have that kind of success. Many never get a drug on the market. In fact, a drug entering human trials has only about a 1 in 10 chance of being approved. So it makes sense that the rewards need to be large to take on that kind of risk. Since these stocks can be very speculative, there are a few things you can do to lower your risk. - Place a [trailing stop](. I recommend using a 25% trailing stop on most trading positions. That means you raise the stop as the stock moves higher. That can help limit your losses if things go wrong. - Position size accordingly. I recommend never putting more than 4% of your risk capital into any one position. That way, if you get stopped out for a 25% loss, you've lost only 1% of your total capital. - Keep an eye on catalysts.[Small biotech stocks]( don't often react to earnings reports like most stocks do. But they can fly around after the release of clinical trial data or a presentation at an important conference. Be aware of when data is coming out or when a company is scheduled to present at a conference so you can pay attention to how the stock responds to news. Companies will usually issue press releases mentioning the dates they're presenting at conferences. Specific dates for clinical data releases are usually not announced ahead of time. Rather, companies will give a rough time frame for the data release, such as "first quarter of the year." That said, Wall Street has been watching [one specific catalyst]( for decades. And this one comes with an exact date. Using it, you could [double your money 12 times over the next 12 months](. [Click here to learn how.]( You can hit some big home runs in the [biotech sector]( but you need to manage your risk when trading these stocks. If you handle your risk properly, you'll be able to take more big swings and hit one of those portfolio-altering gains. Good investing, Marc [Leave a Comment](  MORE FROM PROFIT TRENDS [3 Renewable Energy ETFs to Power Your Portfolio](    [Space Stocks: The Space Race Is Heating Up](    [Considering Nikola or Tesla? Buy This EV Company Instead](  [Facebook]( [Facebook]( [Twitter]( [Twitter]( [Email Share](mailto:?subject=A%20great%20piece%20from%20Profit%20Trends...&body=From%20Profit%20Trends:%0D%0A%0D%0ABiotech%20stocks%20can%20be%20risky,%20but%20people%20who%20know%20how%20to%20manage%20them%20can%20see%20big%20gains.%0D%0A%0D [Email Share](mailto:?subject=A%20great%20piece%20from%20Profit%20Trends...&body=From%20Profit%20Trends:%0D%0A%0D%0ABiotech%20stocks%20can%20be%20risky,%20but%20people%20who%20know%20how%20to%20manage%20them%20can%20see%20big%20gains.%0D%0A%0D  SPONSORED [Congress]( When I Thought Congress Couldn't Get Any Dumber...]( It Goes and Passes the Worst Financial Bill in History - 417-3. [Go Here to Find Out How It Could Impact YOUR IRA or 401(k).](  [The Oxford Club]  You are receiving this email because you subscribed to Profit Trends. Profit Trends is published by The Oxford Club. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Profit Trends]( | [Unsubscribe]( © 2020 The Oxford Club, LLC All Rights Reserved The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#) North America: [1.800.589.3430](#) | International: [+1.443.353.4334](#) | Fax: [1.410.329.1923](#) [Oxfordclub.com](   The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.